<DOC>
	<DOCNO>NCT01671449</DOCNO>
	<brief_summary>A multicenter , randomize , open-label , phase III trial S-1 plus cisplatin ( 3 weekly ) versus S-1 plus oxaliplatin chemotherapy first-line treatment advance gastric cancer</brief_summary>
	<brief_title>S-1 Cisplatin ( 3 Weekly ) Versus S-1 Oxaliplatin Combination Chemotherapy Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Written inform consent enrollment 2 . Age ≥18 year old 3 . Histologically/cytologically confirm recurrent metastatic gastric esophagogastric junctional adenocarcinoma 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 5 . Patients able swallow food drug 6 . At least one measurable evaluable lesion accord RECIST criterion version 1.1 7 . Adequate bone , hepatic , renal function assess follow laboratory requirement conduct within 7 day prior first administration study drug Absolute neutrophil count ( ANC ) ≥ 1,500/ uL , platelet ≥ 100,000/ uL , haemoglobin ( Hb ) ≥ 9.0 g/dl , Serum creatinine ≤ 1.5 mg/dL ( If serum creatinine great 1.5 mg/dL , creatinine clearance [ Ccr ] 60 mL/min great . Ccr calculate CockcroftGault formula 24hr urine collection ) Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , AST/ALT level ≤ 3.0 x ULN ( AST/ALT level ≤ 5.0 x ULN patient liver involvement cancer ) 8 . In patient receive adjuvant neoadjuvant chemotherapy , completion systemic chemotherapy 6 month study enrollment , previous administration platinum derivative 9 . Estimated life expectancy 3 month 1 . Other histologic type adenocarcinoma 2 . Recurrence within 24 week follow completion adjuvant chemotherapy 3 . R1 gastrectomy ( i.e. , microscopic residual disease ) 4 . History another malignancy within last five year day write informed consent except cure basal cell carcinoma skin cure carcinoma situ uterine cervix 5 . Radiotherapy within 4 week randomization 6 . History significant neurologic psychiatric disorder , presence history CNS metastasis 7 . Major surgery within 4 week study entry , insufficient recovery major surgery ( except patient receive open closure biopsy ) 8 . Other serious illness medical condition follow ; Any follow condition occur within 6 month study entry : myocardial infarction , severe/unstable angina , bypass surgery coronary artery/peripheral artery , congestive heart failure ( NYHA class III IV ) , cerebral infarction transient ischemic attack Conduction abnormality 2nd degree great AV block severe arrhythmia require medical treatment ( right bundle branch block ( RBBB ) eligible , leave bundle branch block ( LBBB ) . ) Uncontrolled hypertension Liver cirrhosis ( Child Pugh Class B great ) Interstitial pneumonia , pulmonary fibrosis Active viral hepatitis B Uncontrolled diabetes mellitus Uncontrolled ascites pleural effusion Uncontrolled active infection sepsis 9 . Administration medication may potentially pharmacokinetic interaction S1 , cisplatin , oxaliplatin Flucytosine , fluorinated pyrimidine antifungal agent Antiviral agent , sorivudine , brivudine , chemical similar drug Warfarin ( except , low dose warfarin purpose prophylaxis ) , phenprocoumon Phenytoin Allopurinol 10 . Participation clinical trial administration investigational drug within 30 day randomisation 11 . Pregnant lactate woman 12 . Women men child bear potential employ adequate contraception study treatment 3 month end study treatment 13 . Ineligible study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>